cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Stockal+Disclaimer.pdf
21 own
8 watching
Current Price
$27.17
$-0.58
(-2.09%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,746.78M
52-Week High
52-Week High
45.58000
52-Week Low
52-Week Low
15.90000
Average Volume
Average Volume
1.4M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization2,746.78M
icon52-Week High45.58000
icon52-Week Low15.90000
iconAverage Volume1.4M
iconDividend Yield--
iconP/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Zolmax
10 months ago
Shares of Immunovant, Inc. (NASDAQ:IMVT Get Rating) have been assigned an average rating of Moderate Buy from the eleven brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the ...
Zolmax
1 year ago
Immunovant, Inc. (NASDAQ:IMVT Get Rating) CEO Peter Salzmann sold 3,395 shares of the companys stock in a transaction on Tuesday, April 18th. The shares were sold at an average price of $15.27, for a total value of $51,841.65. Following the transaction, the chief executive officer now directly owns ...
Ticker Report
1 year ago
Immunovant, Inc. (NASDAQ:IMVT Get Rating) CFO Eva Renee Barnett sold 3,423 shares of the firms stock in a transaction on Tuesday, April 18th. The shares were sold at an average price of $15.27, for a total value of $52,269.21. Following the sale, the chief financial officer now ...
Zolmax
1 year ago
Immunovant, Inc. (NASDAQ:IMVT Get Rating) Research analysts at HC Wainwright lifted their FY2026 earnings per share estimates for Immunovant in a research note issued on Monday, March 20th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($1.19) for the...
Benzinga
1 year ago
Latest Ratings for IMVT DateFirmActionFromTo Dec 2021Wells FargoInitiates Coverage OnEqual-Weight Nov 2021HC Wainwright & Co.MaintainsBuy Aug 2021BairdDowngradesOutperformNeutral View More Analyst Ratings for IMVT View the Latest Analyst Ratings read more...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$27.17
$-0.58
(-2.09%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
$42.12
$-0.17 (-0.40 %)
SpringWorks Therapeutics Inc
SpringWorks Therapeutics Inc
$45.53
$1.33 (3.01 %)
Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc
$29.32
$0.39 (1.35 %)
Bridgebio Pharma Inc
Bridgebio Pharma Inc
$24.88
$0.55 (2.26 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
$42.12
$-0.17 (-0.40 %)
SpringWorks Therapeutics Inc
SpringWorks Therapeutics Inc
$45.53
$1.33 (3.01 %)
Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc
$29.32
$0.39 (1.35 %)
Bridgebio Pharma Inc
Bridgebio Pharma Inc
$24.88
$0.55 (2.26 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00